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Antibody-mediated pure red cell aplasia is a very rare
but devastating condition affecting patients receiving
treatment with erythropoiesis-stimulating agents. New cases
continue to emerge, generally in clusters, consistent with
an ‘environmental’ trigger to its pathogenesis. Defining the
causes of antibody-mediated pure red cell aplasia is clearly
of importance for patients with chronic kidney disease, but
any developments in this area may also have relevance to
other disease areas as therapeutic delivery of endogenous
proteins rapidly increases. This review focuses on the current
knowledge regarding the etiology of antibody-mediated
pure red cell aplasia and the current approach to therapy.
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Antibody-mediated pure red cell aplasia (PRCA) is charac-
terized by a sudden fall in hemoglobin concentration despite
erythropoiesis-stimulating agent (ESA) therapy, with
reticulocyte counts declining to levels o20 109/l. Affected
patients rapidly become transfusion dependent, and a bone
marrow examination shows absence or near-absence of
erythroid progenitor cells. Antibodies to erythropoietin
(EPO), detectable in the serum of such patients, neutralize
not only the biological activity of the therapeutic ESA, but
also endogenous EPO, thus obliterating red cell production
in the bone marrow.
PRCA related to ESA therapy is rare, with an exposure-
adjusted incidence of 0.02–0.03 per 10,000 patient-years.1 The
peak incidence of PRCA related to ESA therapy occurred
during 2002–2003, following the report of a small case series.2
The majority of these cases were caused by a preparation of
epoetin alfa marketed outside the United States (Eprex/
Erypo). During this time, the exposure-adjusted incidence
rate per 10,000 patient-years for Eprex-associated PRCA
peaked at 4.5.1 The cause of this condition has remained
elusive, although several factors are believed to have been
implicated. The most obvious cause was the removal of
human serum albumin (HSA) from the Eprex preparation,
which was mandated by European law following concerns
about the transmission of Creutzfeldt-Jakob disease. HSA was
replaced by polysorbate 80, and it was initially thought that
the polysorbate itself might be involved in the pathogenesis.
The ‘mixed micelle’ hypothesis has, however, been found to
be less attractive than was initially thought, and the ‘rubber
leachates’ hypothesis has also been challenged. Another factor
in the pathogenesis of this condition was believed to be a
break in the cold storage chain, thus rendering the protein
molecule less stable.
Despite these explanations, there are still unanswered
questions. For example, cases of PRCA were not seen exclu-
sively in patients receiving HSA-free epoetin alfa, but also in
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patients receiving epoetin beta and darbepoetin alfa. Also, if
the ‘rubber leachates’ hypothesis was correct, why did only a
very small fraction of the patients develop this condition?
Following a flurry of literature in the period 2002–2007, the
scientific world has gone quiet regarding this condition.
However, new cases continue to develop across Europe and
elsewhere.3,4 At the time of writing, five new cases have been
detected in the United Kingdom alone over the last 6 months,
a case of antibody-mediated PRCA in a patient treated
exclusively with intravenous epoetins has been reported,5 and
the first case in a patient receiving methoxy polyethylene
glycol–epoetin beta (Mircera) has emerged.6 In addition, one
definite case of PRCA and one possible case have emerged
during a clinical trial of a biosimilar EPO involving only 337
patients.7 This trial was aborted, and the manufacturer of this
biosimilar EPO embarked on an extensive investigation into
the possible root cause of this problem.8
ROOT CAUSES OF INCREASED IMMUNOGENICITY OF ESAs
Product-related factors
Following the increase in PRCA associated with Eprex/Erypo,
the manufacturer initiated a program of investigations to
identify possible causes. However, the question of exactly
how the change in formulation of this product led to
increased immunogenicity has not been fully resolved. The
answer is important not only for the safety evaluation of
future ESAs, but also for the development of therapeutic
proteins in general.
As epoetins, like many other biopharmaceuticals, are
recombinant versions of human proteins, the issue is one of
autoimmunity and more specifically the breaking of B-cell
tolerance. The mechanisms by which tolerance is broken are
not completely understood. Many factors have been reported
to influence immunogenicity (Figure 1); the primary factor
responsible for activation of autoreactive B cells, supported
by clinical and experimental data, is the presence of
aggregates.9,10 The hypothesis is that the periodicity of self-
antigens present in protein aggregates resembles the repeated
self-epitope structure of viral capsids that is capable of
directly activating B cells.
Several explanations have been offered to explain how
the exchange of HSA with polysorbate 80 led to an increase
in the incidence of PRCA associated with Eprex/Erypo.
Any plausible explanation should be based on experimental
data and have a sound biological rationale. It should also be
consistent with epidemiological data such as the rarity and
uneven geographic distribution of PRCA. One explanation
involved organic leachates from the uncoated rubber stoppers
of pre-filled syringes, which were proposed to act as
adjuvants for T-cell–mediated activation of the anti-EPO
immune response. There are several reasons why this expla-
nation is unlikely. First, the level of self-tolerance to EPO
is very high, because an autoimmune response to this
self-protein would be lethal; indeed, there is only one report
of a case of PRCA caused by spontaneous production of
antibodies.11 Second, the leachates failed to show any effect
on the immunogenicity of Eprex/Erypo in a mouse model;12
given the high degree of homology between the amino-acid
sequences of human and murine EPO, this lack of effect
argues against the involvement of leachates in breaking B-cell
tolerance. Leachates did yield a positive, concentration-
dependent antibody response in the same model immunized
with ovalbumin; however, the appropriateness of this
model is questionable, given that ovalbumin is a foreign
protein. The antibody response in this system is more likely a
classical immune reaction to a foreign protein, not a loss of
self-tolerance. The leachates hypothesis is also inconsistent
with the epidemiological data; regional differences in
incidence are difficult to explain with leachate adjuvants
being present in every syringe. There was also no discus-
sion of the cumulative effect of repeated exposure to low
concentrations of leachates, and no explanation has been put
forward for the mechanism by which leachates could behave
as adjuvants.
A second explanation involves the formation of poly-
sorbate 80 micelles containing protein, which were proposed
to break tolerance by presenting epoetin to B cells in an array
form.13 However, their low concentration and instability
make EPO-containing micelles a questionable mechanism for
breaking B-cell tolerance. This hypothesis is also inconsistent
with the epidemiological data because the micelles would also
have been present in all syringes containing the reformulated
product.
The theory based on aggregate formation, made more
likely following the formulation change in Eprex/Erypo, is
consistent with all available data and is supported by
substantial experimental evidence from other therapeutic
proteins.14 Eprex/Erypo has been reported to contain
increasing levels of aggregates with prolonged duration of
storage, and the tendency for aggregate formation could be
exacerbated by a high concentration of polysorbate 80.15 A
role for aggregation is also consistent with the epidemio-
logical patterns. HSA was a more efficient stabilizer of epoetin
than polysorbate 80; following the change of formulation,
mishandling of less stable products would be more likely
to induce aggregation. Divergent handling methods could
Product-related factors:
• Impurities (e.g., leachates)
• Formulation (e.g., stabilizers)
• Tungsten-induced aggregation
Route of administration:
• Subcutaneous vs. intravenous
• Inappropriate storage/














Figure 1 | Factors involved in the pathogenesis of
erythropoiesis-stimulating agent (ESA)–induced pure red cell
aplasia (PRCA).
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therefore explain the geographical distribution of ESA-
associated PRCA. Later reports of immunogenicity problems
with epoetins also support the proposal that aggregation
induced by mishandling was the root cause of the spike in
PRCA associated with Eprex/Erypo. Several cases of PRCA
have been reported in Thailand associated with Eprex.16
Mishandling resulting in aggregate formation was suggested
as the reason for these cases.
There have also been cases of antibody-mediated PRCA
reported following the use of locally manufactured epoetins
in Latin America and Asia.17,18 These alternative biological
products (manufactured outside of Europe and the United
States) should be distinguished from true biosimilar epoetins,
which are approved under a strict regulatory pathway such as
the one set out by the European Medicines Agency.19–24
Biosimilar epoetins approved under the European Medicines
Agency regulatory pathway are required to undergo extensive
physicochemical characterization to confirm their similarity
to the originator product.25 The European Medicines Agency
biosimilar regulatory pathway also requires clinical trial data
in at least one representative indication and a compre-
hensive risk management plan.19–22 The alternative biological
products manufactured in Latin America and Asia typically
required only bioequivalence data to gain marketing approval
(as for conventional generic medicines), with no requirement
for clinical trial data or formal pharmacovigilance.18 To date,
pharmacovigilance infrastructure in these territories has
been lacking or inadequate, and therefore problems of
immunogenicity are likely to have been underreported. It is
important that such infrastructure is established to improve
detection of adverse effects with biopharmaceuticals. In
addition, analytical studies of these alternative products have
shown that they vary in composition, indicating inadequate
control over manufacturing processes.26,27
Following two cases of neutralizing antibodies (NAbs) in
patients receiving subcutaneous HX575,7 the manufacturer of
this product initiated investigations to identify the possible
root cause(s) of these adverse events. They have recently
reported that pre-filled syringes containing HX575, impli-
cated in two cases of NAbs, contained unexpectedly high
levels of protein aggregates and tungsten. At least a propor-
tion of the aggregates appeared to be dimers covalently
linked by disulfide bonds.8 Spiking of non-suspect batches of
the medication with sodium polytungstate, or with an extract
of tungsten pins used to manufacture the syringes, induced
the formation of aggregates with similar properties; in
addition, tungsten (sodium polytungstate) was shown to
have a strong denaturing effect on the protein.8 It is proposed
that the tungsten species in the syringes caused HX575
protein to unfold, with subsequent formation of aggregates.
This hypothesis is inherently attractive, as several other
reports have also implicated tungsten in the aggregation
of pharmaceutical protein products.28–30 Further work to
fully characterize these tungsten-induced dimers/aggregates is
required to determine the epitopes responsible for immuno-
genicity. The tungsten is most likely to originate from
tungsten pins used to form the barrels of the glass syringes in
which the final product is provided for use.30 As the syringes
and needles are generally provided by a single supplier,
this possibly explains why PRCA has been recognized with
multiple ESA products. Furthermore, it is likely that the
leaching of tungsten into the syringe occurs in a variable
manner based on the life of the tungsten pin used. These
findings may be more broadly applicable not only to other
ESAs but also to other classes of therapeutic proteins. Given
these novel findings, it may be prudent for manufacturers
of therapeutic proteins to routinely determine the tungsten
content of their syringes, and consider switching to
alternative strategies to generate the barrels of their glass
syringes in order to minimize the risk of protein aggregation
and an immunogenic response.
Route of administration
In general, intravenous administration of a protein is much
less likely to evoke an immune response than intranasal,
intramuscular or subcutaneous administration.31 For
example, in one study the incidence of anti-interferon anti-
bodies in patients treated subcutaneously was 10 times the
rate among patients treated intravenously.32 This may be
due to the high concentration of antigen-presenting cells in
the skin and/or the longer availability of the administered
protein due to the slower rate of resorption.33 This process
is reflected in a case report of a patient with PRCA who
repeatedly developed wheals at sites of former subcutaneous
administration following intravenous administration of
Eprex.34 In addition, the subcutaneous route increases the
possibility of self-administration and therefore inappropriate
storage/handling at home.35 It is clear that the majority of
reported antibody-positive PRCA cases occurred in patients
receiving epoetins by the subcutaneous route.36 Two cases in
which PRCA developed following intravenous administration
of epoetin have been mentioned in the literature,37 although
a follow-up with the authors could not confirm that these
cases involved intravenous use exclusively. A very recent
report from Japan describes what appears to be the only
confirmed report of PRCA arising solely from intravenous
administration of epoetin, with the patient receiving both
epoetin alfa and darbepoetin alfa on separate occasions.5
Duration of treatment
In the original case series reported by Casadevall et al.,2 the
interval from the start of therapy to EPO-refractory anemia
ranged from 3 to 67 months. In a review of all cases of ESA-
induced PRCA known up to April 2004, the median duration
of treatment before PRCA was diagnosed was 9.1 months for
patients receiving Eprex, 24.8 months for patients receiving
Epogen, and 18.0 months for patients receiving NeoRecor-
mon.36 Sporadic cases reported in other indications also
occurred after prolonged treatment.38 A possible explanation
for the longer median duration of treatment with Epogen is
that this agent is used primarily in the United States, where it
is predominantly administered intravenously, while the other
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agents are used in Europe and elsewhere, with a greater
proportion of subcutaneous administration. As described
previously, intravenous administration of a protein is much
less likely to evoke an immune response than subcutaneous
administration.
However, these intervals may not be truly representative of
the duration of treatment required for anti-EPO Abs to be
generated. First, these data include PRCA cases from a period
when a formulation change resulted in a product that was
clearly more immunogenic than earlier and subsequent
formulations. Second, nephrologists are now much more
aware of PRCA, and are likely to more promptly initiate
appropriate investigations in patients who exhibit a sudden
decrease in blood hemoglobin levels and reticulocyte counts.
Previously, it is possible that physicians were more likely to
respond to such a situation by escalating the ESA dose or
switching to an alternative product. In routine clinical
practice, blood samples are tested for binding and NAbs
only after resistance to ESA therapy is apparent. In reality,
therefore, the period until antibodies form is likely to be
shorter than previously indicated, and anti-EPO antibodies
may be present after 3 months of therapy.
The duration of treatment has been proposed to explain,
at least in part, why no cases of PRCA have been reported in
patients with cancer receiving ESAs for chemotherapy-
induced anemia, who typically receive ESA treatment for a
much shorter period than patients with renal anemia. Such
patients may also have a compromised immune response
because of the myelosuppressive effects of chemotherapy.35 It
is also possible that PRCA has not been diagnosed in this
population because of a low index of suspicion, with severe
anemia attributed to marrow suppression by the chemo-
therapy itself or to the effects of the tumor.
Patient characteristics
As PRCA is a very rare and geographically and temporally
disparate condition, with an often insidious onset, it is
difficult to properly identify common themes and features.
There may be only handfuls of accurately identified cases in
any country at any one time, so it may be years before
individual doctors or even teams of nephrologists recognize a
case, or a series of cases.
It is apparent that the normal tolerance to foreign proteins
(amino acids and sugar moieties) breaks down under
selected, largely unpredictable, circumstances, to allow the
production of specific NAbs. Under more normal conditions,
there is immunological accommodation, if not true tolerance,
to exogenous proteins, that is, ‘broken’ by clinical events—
perhaps infection, intercurrent illness, or adjuvant therapies
(e.g., tungsten or aggregates). This most likely relates to a
complex and unpredictable interaction between the patient’s
immunological status (genotype and phenotype) and the
protein in question, and additional factors such as the
catalytic or tolerance-breaking effects referred to above. It is
clearly a considerable co-incidental effort for the immuno-
logical accommodation to be overcome, and therefore
almost impossible to screen for subjects who might be
susceptible.
Several patient-related factors appear to be relevant, but
may be of little or no use for screening. The genetic
background of the patient can influence whether antibodies
are produced;39 the major histocompatibility complex allele
affects antigen recognition in T-lymphocyte–mediated re-
sponses. Follow-up investigations into the cluster of anti-
body-positive PRCA cases reported in Thailand focused on
HLA-DRB1*9, a major histocompatibility complex allele that
is much more common in Thais than in Caucasians.40 Thai
patients who were carriers of this allele were more likely to
have developed PRCA than a control group consisting of
kidney transplant candidates,41 and a similar finding has
been reported in Caucasian patients.42 However, cases also
developed in patients who were not carriers of this allele.
This suggests that while this major histocompatibility
complex allele may contribute to the susceptibility to
developing anti-EPO antibodies, it is not an absolute
requirement.
It has been noted that there is an excess of elderly males
among cases of ESA-related PRCA.36 The two cases of NAbs
with HX575 also occurred in elderly male patients.7 However,
as most cases occur outside of clinical trials, there is only
limited information about the characteristics of the patients
involved. An updated analysis would be of interest to
establish if elderly males, or other patient groups, are at
increased risk of PRCA secondary to ESA treatment.
CD4 T cells have a central role in the humoral immune
response, and a recent study has quantified the number of
EPO-specific CD4 T cells in the blood of normal donors.43
These investigations identified an important repertoire of
pre-existing EPO-specific T cells in almost half of the donors,
comparable to that of non-self-proteins. The authors suggest
that, at steady state, endogenous EPO contributes weakly to
induction of tolerance and may be ignored by the immune
system. Consequently, circulating EPO-specific CD4 T cells
could be susceptible to activation by altered batches of
exogenous EPO, providing them with co-stimulatory signals.
These data also suggest that T-cell assays in normal donors
may be useful in determining the immunogenic potential
of therapeutic proteins.43 This is interesting and potentially
promising work, but overall the science of drug-induced
immunological changes is not given the prominence,
funding, and priority it deserves.
Diagnosis and treatment of ESA-induced PRCA
PRCA is a primary hematologic disease, but can also occur as
a result of various infections, hematologic malignancies,
autoimmune diseases, severe malnutrition, and exposure to
certain drugs and toxins.3 The first clinical sign of ESA-
induced PRCA is severe resistance to treatment, which mani-
fests as a rapid decline in hemoglobin levels to 5–6 g/dl
or transfusion dependence. On exclusion of other causes of
ESA hyporesponsiveness, measurement of blood cell counts
should be performed; a reticulocyte count of o10 109/l in
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the presence of normal white cell and platelet counts justifies
bone marrow examination and measurement of anti-EPO
antibodies.3 Although bone marrow examination in a patient
with ESA-induced PRCA will usually demonstrate an absence
of erythroblasts, the diagnosis is confirmed by the presence of
neutralizing anti-EPO antibodies.3 The presence of circulat-
ing anti-EPO antibodies is usually determined with an
immunoassay (radioimmunoprecipitation or enzyme-linked
immunosorbent assay) or surface plasmon resonance methods;3
samples that are positive for the presence of anti-EPO
antibodies are then tested for the presence of EPO-NAbs
using a cell-based bioassay.
Antibody-mediated PRCA is very rarely self-limiting and
usually necessitates therapeutic intervention. The most
important initial steps in its management are to stop the
further administration of ESA therapy and to treat the
anemia with red blood cell transfusions.
The therapeutic approach is based on the use of immuno-
suppressive therapies.44 The most effective treatment, with
almost complete recovery, is kidney transplantation.44,45
Transplanted patients also receive immunosuppressive
therapy as part of their anti-rejection protocol, and it is
unclear whether the success of this strategy is related to this
therapy or to the transplant itself. Corticosteroids and
cyclosporin A, alone or in combination, seem beneficial.45
Several small studies indicate that cyclosporin A alone
induces rapid recovery and could be proposed as first-line
therapy.45,46 Based on these studies, typical starting doses
for immunosuppressive therapies are 0.5–1.0 mg/kg/day for
corticosteroids and 200 mg/day for cyclosporin; patients who
respond to these therapies would be expected to recover
(as indicated by transfusion independence and increases in
reticulocytes or hemoglobin) within 3 months.
A challenge for nephrologists is whether ESA therapy can
be re-started in patients who have recovered from PRCA with
disappearance of NAbs. Re-challenge with an ESA can cause
a relapse,47 and may induce systemic reactions.34 Successful
re-challenge has been observed in isolated cases, although this
should be carefully considered and should preferentially use
intravenous administration.48
A study has shown that a novel synthetic peptide-based
EPO receptor agonist (peginesatide) can correct anemia in
chronic kidney disease patients with antibody-mediated
PRCA.4 This small clinical trial in 14 patients indicated a
high success rate for peginesatide in rescuing patients with
this condition. The biological rationale for the use of
peginesatide in this setting is based on the fact that the
amino-acid sequence is different from that of recombinant
EPO, and thus it does not cross-react with anti-EPO
antibodies.
The therapeutic recommendations for chronic kidney
disease patients with ESA-induced PRCA would therefore
be (Figure 2): (1) cessation of ESA therapy; (2) correction
of anemia with blood transfusions if necessary; (3) consid-
eration of kidney transplantation as the most effective
treatment; (4) introduction of immunosuppressive therapy
starting with cyclosporin A alone or in combination with
corticosteroids, or corticosteroids with cyclophosphamide.
In the future, as an alternative to immunosuppressive therapy,
peginesatide could be a promising treatment, although at the
time of writing this remains an unlicensed investigational
drug.
CONCLUSIONS
PRCA remains an extremely rare adverse effect of treatment
with ESAs, although cases continue to emerge across the
product class. As with any rare disease or complication of
therapy, the pathogenesis will only be defined through close
cooperation of clinicians, scientists, the pharmaceutical
industry, regulators, and patients. Advances are being made
in delineating the root causes of antibody-mediated PRCA,
with the most recent and plausible explanation being the
leaching of tungsten (from the tungsten pins used in the
manufacture of glass syringes) into the syringe contents. This
explanation has widespread applicability to ESA treatment
and potentially to other therapeutic proteins.
Therapy to date has relied on systemic immunosuppres-
sion to impair immunological responsiveness. The use of
peptide mimetics is a promising development, but of itself
will not modify production of antibodies to EPO.
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Figure 2 |Proposed treatment algorithm for erythropoiesis-
stimulating agent (ESA)–induced pure red cell aplasia.
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